Oppenheimer Reiterates Outperform on Chemed Corporation (CHE) After Meeting with Management

September 26, 2016 9:53 AM EDT
Get Alerts CHE Hot Sheet
Price: $143.66 +1.64%

Rating Summary:
    0 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 11
Trade CHE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Oppenheimer reiterated an Outperform rating and $155.00 price target on Chemed Corporation (NYSE: CHE) after attending meetings with management. The company has acknowledged that admissions have been disappointing in 2016, as competitors have been more aggressive around increasingly profitable shorter-stay patients. However, Chemed's balance sheet remains among the cleanest in Oppenheimer's view, at 0.6X EBITDA.

Analyst Michael Wiederhorn commented, "We attended meetings with the management team for Chemed. We believe the company should continue to make the most out of a challenging 2016, while 2017 should represent a return to the solid organic growth levels investors are accustomed to. With strong balance sheet/cash flow profile, limited exposure to the ACA and a stable reimbursement outlook, we believe Chemed remains an attractive longer-term investment in a rocky healthcare universe."

For an analyst ratings summary and ratings history on Chemed click here. For more ratings news on Chemed click here.

Shares of Chemed closed at $141.29 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment